OCC 0.80% 63.0¢ orthocell limited

Ann: CelGro Nerve Regeneration Results in Quadriplegic Patients, page-200

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 14,848 Posts.
    lightbulb Created with Sketch. 286
    The rat models for peripheral nerve regeneration looked really good (comparison of GelGro nerve regen. versus suture). They need to do the same with humans otherwise there's no basis for comparing Celgro versus standard treatment. If there's no basis for comparison, then there's no telling if it's an advancement on suturing. Geting a neurosurgeon on board would be a good thing. They are the ones who are usually tasked with doing these sorts of procedures. Taking meaurements for opiate use is immaterial because ruptured peripheral nerves are not usually painful. Lots of problems with methodology and data presentation need ironing out. Outsourcing the research side of things to a university might be an option.

    Don't blame me for the share price drop. It would have happened anyway. I wouldn't be the only one thinking like this. There's huge potential, but it needs to be properly demonstrated.
    Last edited by float^: 10/10/19
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
63.0¢
Change
0.005(0.80%)
Mkt cap ! $148.2M
Open High Low Value Volume
63.5¢ 64.0¢ 61.5¢ $130.1K 207.5K

Buyers (Bids)

No. Vol. Price($)
3 29715 62.5¢
 

Sellers (Offers)

Price($) Vol. No.
63.0¢ 23412 4
View Market Depth
Last trade - 11.25am 18/11/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.